Stiripentol is a novel antiepileptic drug specifically designed to treat rare and severe epilepsy.

Drug name

Common name: Stiripentol

Product Name: DIACOMIT ®

indication

Used for treatment:

Dravet syndrome patients aged 2 years and above: need to use in combination with clobazam

Not recommended: as a monotherapy for Dravet syndrome

Specifications and characteristics

Capsules:

250mg: Pink, printed with "Diacomit" and "250mg"

500mg: white, printed with "Diacomit" and "500mg"

Oral suspension powder:

250mg/pack: light pink fruit flavored powder

500mg/pack: light pink fruit flavored powder

main ingredients

Active ingredient: Streptopentanol

Accessories:

Capsules: gelatin, magnesium stearate, polyvinylpyrrolidone, etc

Suspension agents: Aspartame, Sodium Carboxymethylcellulose, Glucose, etc

Usage and Dosage

Recommended dosage: 50mg/kg/day, taken in 2-3 doses

Maximum dose: 3000mg/day

Medication requirements:

Capsules: Take whole capsule with meals, do not break or chew

Suspension: Take immediately after mixing 100mL of water with meals

Missed medication: Take it as soon as possible, skip if it is close to the next medication time

Vomiting: No need for supplementation

Dose adjustment

Sleepiness: Consider reducing the dose of chlorpromazine by 25%

Diarrhea:

Level 3 no anti diarrhea treatment: pause until the original dose is restored and continue

Level 3 anti diarrhea treatment: pause until reduced after recovery

Level 4: Permanent discontinuation of medication

Hepatotoxicity:

Elevated level 2 bilirubin: pause until recovery and continue with the original dose

Level 3 ALT/AST or bilirubin elevation: pause until reduced after recovery

Level 4: Permanent discontinuation of medication

Medication precautions

Diet: Must be taken with meals

Monitoring requirements:

Blood routine examination before treatment and every 6 months

Regular monitoring of weight gain (children)

Beware of suicidal tendencies

Taboo:

Avoid alcohol

Suspension containing phenylalanine should be used with caution in patients with phenylketonuria

Medication for special populations

Pregnancy/lactation:

Pregnancy: May cause malformations, contraception is necessary during treatment and after discontinuation of medication

Breastfeeding: Not recommended

Children: Safe and effective for patients aged ≥ 2 years old

Liver dysfunction: moderate to severe requiring reduction in dosage

Renal insufficiency: Not recommended for moderate to severe cases

adverse reaction

Common (≥ 10%):

Sleepiness (67%), decreased appetite (45%), ataxia (27%), weight loss (27%), low muscle tone (24%), nausea (15%), tremor (15%)

Serious:

Neutropenia (13%), thrombocytopenia (13%), suicidal tendencies

contraindication

No absolute contraindications

Drug interactions

Chlorpromazine: Increase its blood concentration and reduce it

CYP3A4/CYP2C19 substrates: may require reduction

CYP1A2/CYP3A4/CYP2C19 Strong Inducing Agents: Avoid Combination Use

Storage method

Store at 20-25 ° C, keep away from light in original packaging

Take the suspension immediately after preparation

Diacomitinformation